α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis

Monica Morini, Luca Roccatagliata, Raffaella Dell'Eva, Enrico Pedemonte, Roberto Furlan, Simona Minghelli, Debora Giunti, Ulrich Pfeffer, Monica Marchese, Douglas Noonan, Gianluigi Mancardi, Adriana Albini, Antonio Uccelli

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

α-Lipoic acid (α-LA) is a neuroprotective metabolic antioxidant that has been shown to cross the blood brain barrier. We tested whether α-LA is capable to prevent MOG35-55-induced experimental autoimmune encephalomyelitis (EAE), an established model of multiple sclerosis (MS). Daily oral administration of α-LA, starting at the time of immunization, significantly prevented EAE progression as compared to control mice. This was associated with a reduction of CNS infiltrating T cells and macrophages as well as decreased demyelination. We then tested α-LA in a therapeutic protocol aimed at suppressing EAE after its onset. Intraperitoneal (i.p.), but not oral, administration of α-LA significantly prevented disease progression when compared to vehicle-treated controls. Similarly, we observed significant reduction of demyelination and inflammatory infiltration. This clinical effect was not due to an impairment of MOG35-55 recognition by encephalitogenic T cells. In contrast, MOG-specific T cells showed a decreased production of IFNγ and IL-4, suggesting an immunosuppressive activity on both Th1 and Th2 cytokines. In addition, α-LA inhibited the proteolytic activity of MMP2 and MMP9 only at very high doses. Our data indicate that α-LA can effectively interfere with the autoimmune reaction associated with EAE through mechanisms other than its antioxidant activity and supports further studies on the use of α-LA as a potential therapy for MS.

Original languageEnglish
Pages (from-to)146-153
Number of pages8
JournalJournal of Neuroimmunology
Volume148
Issue number1-2
DOIs
Publication statusPublished - Mar 2004

Fingerprint

Thioctic Acid
Autoimmune Experimental Encephalomyelitis
Demyelinating Diseases
T-Lymphocytes
Multiple Sclerosis
Oral Administration
Antioxidants
Therapeutics
Immunosuppressive Agents
Blood-Brain Barrier
Interleukin-4
Disease Progression
Immunization
Macrophages
Cytokines

Keywords

  • Anti-oxidant
  • Experimental autoimmune encephalomyelitis
  • Inflammation
  • Invasion
  • Multiple sclerosis

ASJC Scopus subject areas

  • Immunology
  • Clinical Neurology
  • Immunology and Allergy
  • Neurology

Cite this

α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. / Morini, Monica; Roccatagliata, Luca; Dell'Eva, Raffaella; Pedemonte, Enrico; Furlan, Roberto; Minghelli, Simona; Giunti, Debora; Pfeffer, Ulrich; Marchese, Monica; Noonan, Douglas; Mancardi, Gianluigi; Albini, Adriana; Uccelli, Antonio.

In: Journal of Neuroimmunology, Vol. 148, No. 1-2, 03.2004, p. 146-153.

Research output: Contribution to journalArticle

Morini, M, Roccatagliata, L, Dell'Eva, R, Pedemonte, E, Furlan, R, Minghelli, S, Giunti, D, Pfeffer, U, Marchese, M, Noonan, D, Mancardi, G, Albini, A & Uccelli, A 2004, 'α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis', Journal of Neuroimmunology, vol. 148, no. 1-2, pp. 146-153. https://doi.org/10.1016/j.jneuroim.2003.11.021
Morini, Monica ; Roccatagliata, Luca ; Dell'Eva, Raffaella ; Pedemonte, Enrico ; Furlan, Roberto ; Minghelli, Simona ; Giunti, Debora ; Pfeffer, Ulrich ; Marchese, Monica ; Noonan, Douglas ; Mancardi, Gianluigi ; Albini, Adriana ; Uccelli, Antonio. / α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. In: Journal of Neuroimmunology. 2004 ; Vol. 148, No. 1-2. pp. 146-153.
@article{62b48625b9b2438db7e8fd19d9ca1880,
title = "α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis",
abstract = "α-Lipoic acid (α-LA) is a neuroprotective metabolic antioxidant that has been shown to cross the blood brain barrier. We tested whether α-LA is capable to prevent MOG35-55-induced experimental autoimmune encephalomyelitis (EAE), an established model of multiple sclerosis (MS). Daily oral administration of α-LA, starting at the time of immunization, significantly prevented EAE progression as compared to control mice. This was associated with a reduction of CNS infiltrating T cells and macrophages as well as decreased demyelination. We then tested α-LA in a therapeutic protocol aimed at suppressing EAE after its onset. Intraperitoneal (i.p.), but not oral, administration of α-LA significantly prevented disease progression when compared to vehicle-treated controls. Similarly, we observed significant reduction of demyelination and inflammatory infiltration. This clinical effect was not due to an impairment of MOG35-55 recognition by encephalitogenic T cells. In contrast, MOG-specific T cells showed a decreased production of IFNγ and IL-4, suggesting an immunosuppressive activity on both Th1 and Th2 cytokines. In addition, α-LA inhibited the proteolytic activity of MMP2 and MMP9 only at very high doses. Our data indicate that α-LA can effectively interfere with the autoimmune reaction associated with EAE through mechanisms other than its antioxidant activity and supports further studies on the use of α-LA as a potential therapy for MS.",
keywords = "Anti-oxidant, Experimental autoimmune encephalomyelitis, Inflammation, Invasion, Multiple sclerosis",
author = "Monica Morini and Luca Roccatagliata and Raffaella Dell'Eva and Enrico Pedemonte and Roberto Furlan and Simona Minghelli and Debora Giunti and Ulrich Pfeffer and Monica Marchese and Douglas Noonan and Gianluigi Mancardi and Adriana Albini and Antonio Uccelli",
year = "2004",
month = "3",
doi = "10.1016/j.jneuroim.2003.11.021",
language = "English",
volume = "148",
pages = "146--153",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier Science B.V.",
number = "1-2",

}

TY - JOUR

T1 - α-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis

AU - Morini, Monica

AU - Roccatagliata, Luca

AU - Dell'Eva, Raffaella

AU - Pedemonte, Enrico

AU - Furlan, Roberto

AU - Minghelli, Simona

AU - Giunti, Debora

AU - Pfeffer, Ulrich

AU - Marchese, Monica

AU - Noonan, Douglas

AU - Mancardi, Gianluigi

AU - Albini, Adriana

AU - Uccelli, Antonio

PY - 2004/3

Y1 - 2004/3

N2 - α-Lipoic acid (α-LA) is a neuroprotective metabolic antioxidant that has been shown to cross the blood brain barrier. We tested whether α-LA is capable to prevent MOG35-55-induced experimental autoimmune encephalomyelitis (EAE), an established model of multiple sclerosis (MS). Daily oral administration of α-LA, starting at the time of immunization, significantly prevented EAE progression as compared to control mice. This was associated with a reduction of CNS infiltrating T cells and macrophages as well as decreased demyelination. We then tested α-LA in a therapeutic protocol aimed at suppressing EAE after its onset. Intraperitoneal (i.p.), but not oral, administration of α-LA significantly prevented disease progression when compared to vehicle-treated controls. Similarly, we observed significant reduction of demyelination and inflammatory infiltration. This clinical effect was not due to an impairment of MOG35-55 recognition by encephalitogenic T cells. In contrast, MOG-specific T cells showed a decreased production of IFNγ and IL-4, suggesting an immunosuppressive activity on both Th1 and Th2 cytokines. In addition, α-LA inhibited the proteolytic activity of MMP2 and MMP9 only at very high doses. Our data indicate that α-LA can effectively interfere with the autoimmune reaction associated with EAE through mechanisms other than its antioxidant activity and supports further studies on the use of α-LA as a potential therapy for MS.

AB - α-Lipoic acid (α-LA) is a neuroprotective metabolic antioxidant that has been shown to cross the blood brain barrier. We tested whether α-LA is capable to prevent MOG35-55-induced experimental autoimmune encephalomyelitis (EAE), an established model of multiple sclerosis (MS). Daily oral administration of α-LA, starting at the time of immunization, significantly prevented EAE progression as compared to control mice. This was associated with a reduction of CNS infiltrating T cells and macrophages as well as decreased demyelination. We then tested α-LA in a therapeutic protocol aimed at suppressing EAE after its onset. Intraperitoneal (i.p.), but not oral, administration of α-LA significantly prevented disease progression when compared to vehicle-treated controls. Similarly, we observed significant reduction of demyelination and inflammatory infiltration. This clinical effect was not due to an impairment of MOG35-55 recognition by encephalitogenic T cells. In contrast, MOG-specific T cells showed a decreased production of IFNγ and IL-4, suggesting an immunosuppressive activity on both Th1 and Th2 cytokines. In addition, α-LA inhibited the proteolytic activity of MMP2 and MMP9 only at very high doses. Our data indicate that α-LA can effectively interfere with the autoimmune reaction associated with EAE through mechanisms other than its antioxidant activity and supports further studies on the use of α-LA as a potential therapy for MS.

KW - Anti-oxidant

KW - Experimental autoimmune encephalomyelitis

KW - Inflammation

KW - Invasion

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=10744226446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744226446&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2003.11.021

DO - 10.1016/j.jneuroim.2003.11.021

M3 - Article

C2 - 14975595

AN - SCOPUS:10744226446

VL - 148

SP - 146

EP - 153

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -